License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	$ 231,495	$ 188,825
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for option exercise	228,800
Development Milestone and Upfront Fee Recognized as Research and Development Expense	500
Collaborative Arrangement | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent research milestone payments	39,800
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense	3,100,000
Development Milestone and Upfront Fee Recognized as Research and Development Expense		100
Collaborative Arrangement | Roche Holding A.G. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	22,000	22,000
Deferred Revenue	552,200
Deferred Revenue, Current	67,200
Deferred Revenue Separate Material Options Right	485,000		$ 485,000
Research and development expense	20,300	$ 17,700
Collaboration Receivable	$ 62,000